Refractory/relapsed acute T lymphoblastic leukemia
Conditions
Interventions
Case series:Intravenous CD7 CAR T cells
Sponsors
Beijing Boren Hospital
Eligibility
Sex/Gender
All
Age
No minimum to 70 Years
Inclusion criteria
Inclusion criteria: 1) Acute T lymphocytic leukemia patients diagnosed with primary drug resistance on the expression of the tumor surface antigen CD7, recurrence of chemotherapy, persistent residual positive or relapse/refractory after allogeneic hematopoietic stem cell transplantation; 2) Male or female patients, aged 0-70 years old; 3) No severe allergies; 4) Physical fitness score 0-2 points; 5) Estimated survival time >=60 days; 6) Bone marrow or peripheral blood or immunohistochemical CD7 positive; 7) Self-knowledgeable patients aged 8-70 voluntarily sign an informed consent form, and the legal representative (guardian) of a child patient under 18 voluntarily signs an informed consent form.
Exclusion criteria
Exclusion criteria: 1) Intracranial hypertension or brain consciousness disorder; 2) Symptomatic heart failure or severe arrhythmia; 3) Symptoms of severe respiratory failure; 4) With other types of malignant tumors; 5) Diffuse intravascular coagulation; 6) Serum creatinine and/or urea nitrogen >=1.5 ULN; 7) Suffer from sepsis or other infections that are difficult to control; 8) Suffer from uncontrollable diabetes; 9) Severe mental disorder; 10) There are obvious intracranial lesions in head MRI examination; 11) Have received an organ transplant (excluding bone marrow transplant); 12) Female patients (patients with fertility) have a positive blood HCG test; 13) Hepatitis (including hepatitis B and C), AIDS and syphilis screening positive. volume_up content_copy share
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety evaluation index;Evaluation index of pharmacokinetics;Efficacy evaluation index; | — |
Countries
China
Contacts
Public ContactJing Pan
Beijing Boren Hosptal
Outcome results
None listed